Long-term Hydromethylthionine Treatment is Associated with Delayed Clinical Onset and Slowing of Cerebral Atrophy in a Pre-symptomatic P301S MAPT Mutation Carrier

Manuscript Number: 

21-0390R1

Author(s): 
Peter Bentham, Charles R. Harrington, Björn O. Schelter, Helen Shiells, Roger T. Staff, Claude M. Wischik

Disclosures

Peter Bentham

  • Sponsors:
    Clinical Advisor - provide advice on study design and interpretation.

Charles R. Harrington

  • Equity:
    I have shares in TauRx Therapeutics Ltd.
    Sponsors:
    I am employed by TauRx Therapeutics Ltd.
    Patents/Royalties
    I am a named inventor on patents owned by WisTa Laboratories Ltd., an affiliate of TauRx in the field of Tau protein and inhibitors of protein aggregation.
    Grants
    • Agency: 
      TauRx Therapeutics Ltd.
      Dates: 
      2002-2021

Björn O. Schelter

  • Sponsors:
    Paid secondment/employment with TauRx Therapeutics Ltd.
    Patents/Royalties
    Named inventor on patents owned by WisTa Laboratories Ltd. or Genting TauRx Diagnostic Centre, affiliates of TauRx.

Helen Shiells

  • Sponsors:
    Employee at TauRx Therapeutics Ltd.
    Patents/Royalties
    Named inventor on patents owned by WisTa Laboratories Ltd. or Genting TauRx Diagnostic Centre, affiliates of TauRx.

Roger T. Staff

  • Consulting Fees:
    I have received consulting fees from TauRx
    Patents/Royalties
    I am a named inventor on patents owned by WisTa Laboratories Ltd

Claude M. Wischik

  • Equity:
    Stock in TauRx Therapeutics
    Sponsors:
    Contract with TauRx Therapeutics
    Patents/Royalties
    I am a named inventor on patents owned by WisTa Laboratories Ltd and Genting TauRx Diagnostic Centre relating to tau protein and neurodegenerative disorders.
    Grants
    • Agency: 
      TauRx Therapeutics Ltd.
      Dates: 
      2002-2021